Based upon a thorough analysis of the respective literature and a comparison of current guidelines, a new proposal for a practical follow-up of patients with non–muscle-invasive bladder cancer (NMIBC) is presented.
Different from other recommendations, the authors paid particular attention to subdivide the so-called intermediate-risk tumors and allocate concrete recommendations for follow-up of this patient group.
This is the first guideline incorporating molecular urine markers in the follow-up of patients with NMIBC.